BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 25350115)

  • 1. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection.
    Brunetto MR; Cavallone D; Oliveri F; Moriconi F; Colombatto P; Coco B; Ciccorossi P; Rastelli C; Romagnoli V; Cherubini B; Teilum MW; Blondal T; Bonino F
    PLoS One; 2014; 9(10):e110782. PubMed ID: 25350115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.
    Yuan Q; Song LW; Cavallone D; Moriconi F; Cherubini B; Colombatto P; Oliveri F; Coco BA; Ricco G; Bonino F; Shih JW; Xia NS; Brunetto MR
    PLoS One; 2015; 10(6):e0130209. PubMed ID: 26115521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients.
    van der Ree MH; Jansen L; Kruize Z; van Nuenen AC; van Dort KA; Takkenberg RB; Reesink HW; Kootstra NA
    J Infect Dis; 2017 May; 215(9):1421-1429. PubMed ID: 28368488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen.
    Ninomiya M; Kondo Y; Kimura O; Funayama R; Nagashima T; Kogure T; Morosawa T; Tanaka Y; Nakayama K; Shimosegawa T
    J Viral Hepat; 2016 May; 23(5):330-9. PubMed ID: 26924666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of quantitative serum HBsAg for optimization of therapy in chronic hepatitis B patients treated with pegylated interferon alfa-2a: a Romanian cohort study.
    Gheorghiţa VI; Caruntu FA; Curescu M; Olaru I; Radu MN; Colţan G; Streinu-Cercel A
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):27-32. PubMed ID: 23539387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.
    Brunetto MR; Oliveri F; Colombatto P; Moriconi F; Ciccorossi P; Coco B; Romagnoli V; Cherubini B; Moscato G; Maina AM; Cavallone D; Bonino F
    Gastroenterology; 2010 Aug; 139(2):483-90. PubMed ID: 20451520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
    Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
    J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].
    Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T
    Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating microRNAs in hepatitis B virus-infected patients.
    Ji F; Yang B; Peng X; Ding H; You H; Tien P
    J Viral Hepat; 2011 Jul; 18(7):e242-51. PubMed ID: 21692939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B.
    Manesis EK; Papatheodoridis GV; Tiniakos DG; Hadziyannis ES; Agelopoulou OP; Syminelaki T; Papaioannou C; Nastos T; Karayiannis P
    J Hepatol; 2011 Jul; 55(1):61-8. PubMed ID: 21145875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma.
    Wang Y; Gao Y; Shi W; Zhai D; Rao Q; Jia X; Liu J; Jiao X; Du Z
    Cancer Biomark; 2015; 15(2):171-80. PubMed ID: 25519019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in serum microRNA profiles in hepatitis B and C virus infection.
    Akamatsu S; Hayes CN; Tsuge M; Miki D; Akiyama R; Abe H; Ochi H; Hiraga N; Imamura M; Takahashi S; Aikata H; Kawaoka T; Kawakami Y; Ohishi W; Chayama K
    J Infect; 2015 Mar; 70(3):273-87. PubMed ID: 25452043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alterations of IFN-γ and IL-4 of peripheral blood T cells in patients with chronic HBV infection].
    Li M; Sun X; Zhou Z; Zhang X; Jin S; Gao Y; Gao Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):240-4. PubMed ID: 26927386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus-Encoded MicroRNA Controls Viral Replication.
    Yang X; Li H; Sun H; Fan H; Hu Y; Liu M; Li X; Tang H
    J Virol; 2017 May; 91(10):. PubMed ID: 28148795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
    Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
    Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
    Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers.
    Park H; Lee JM; Seo JH; Kim HS; Ahn SH; Kim DY; Han KH; Chon CY; Park JY
    Liver Int; 2012 May; 32(5):796-802. PubMed ID: 22128792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.